The upcoming panel discussion on the first year of the Unified Patent Court (UPC) with a focus on pharmaceutical cases promises to be a highly insightful event. This discussion will bring together UPC judges, in-house counsels and leading litigators to examine the initial impact and implications of the UPC's decisions in the pharmaceutical sector.

The panel will explore key topics such as the strategic considerations of opting patents in or out of the UPC system, parallel national and UPC litigation strategies, the court's approach to complex biotech and pharmaceutical patent cases in preliminary injunction and main proceedings, and the implications of the UPC's decisions for future litigation strategies in the pharma industry.

This event will be an essential opportunity for professionals in LESI as well as in the wider licensing and dispute resolution community to gain insights into how the UPC's first year has influenced the sector and what to expect moving forward.

This panel is especially relevant for those involved in pharmaceutical patent litigation, as it will provide critical analysis and predictions for the future, ensuring that participants are well-equipped to navigate the evolving European patent landscape.

MODERATOR: Marleen van den Horst (Partner, LaGro)

PANEL:

Walter Schober (UPC Judge, Local Division Vienna)

Peter Blok (UPC Judge, Court of Appeal Luxembourg)

Kristin Cooklin (Group Head of IP, Recordati)

James Horgan (Chief IP Counsel, MSD)

Thomas Adocker (Partner, Taylor Wessing)